Ergomed PLC
LSE:ERGO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ergomed PLC
Ergomed PLC
Capital Expenditures
Ergomed PLC
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ergomed PLC
LSE:ERGO
|
Capital Expenditures
-£2.5m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Capital Expenditures
-£27.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Capital Expenditures
-£4.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Capital Expenditures
-£36k
|
CAGR 3-Years
29%
|
CAGR 5-Years
15%
|
CAGR 10-Years
32%
|
|
|
C4X Discovery Holdings PLC
LSE:C4XD
|
Capital Expenditures
-£20k
|
CAGR 3-Years
-26%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Capital Expenditures
-£6.7m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-178%
|
CAGR 10-Years
-67%
|
|
Ergomed PLC
Glance View
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm operates approximately 24 offices around the world, providing its services in over 100 countries globally. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.
See Also
What is Ergomed PLC's Capital Expenditures?
Capital Expenditures
-2.5m
GBP
Based on the financial report for Jun 30, 2023, Ergomed PLC's Capital Expenditures amounts to -2.5m GBP.
What is Ergomed PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-12%
Over the last year, the Capital Expenditures growth was -177%. The average annual Capital Expenditures growth rates for Ergomed PLC have been -37% over the past three years , -12% over the past five years .
You don't have any saved screeners yet
